Abstract
Background: Mesenchymal stromal cells (MSCs) may reduce mortality in patients with COVID-19; however, early evidence is based on few studies with marked interstudy heterogeneity. The second iteration of our living systematic review and meta-analysis evaluates a framework needed for synthesizing evidence from high-quality studies to accelerate consideration for approval.
Methods: A systematic search of the literature was conducted on November 15, 2021, to identify all English-language, full-text, and controlled clinical studies examining MSCs to treat COVID-19 (PROSPERO: CRD42021225431).
Findings: Eleven studies were identified (403 patients with severe and/or critical COVID-19, including 207 given MSCs and 196 controls). All 11 studies reported mortality and were pooled through random-effects meta-analysis. MSCs decreased relative risk of death at study endpoint (RR: 0.50 [95% CI, 0.34-0.75]) and RR of death at 28 days after treatment (0.19 [95% CI], 0.05-0.78) compared to controls. MSCs also decreased length of hospital stay (mean difference (MD: -3.97 days [95% CI, -6.09 to -1.85], n = 5 studies) and increased oxygenation levels at study endpoint compared to controls (MD: 105.62 mmHg O2 [95% CI, 73.9-137.3,], n = 3 studies). Only 2 of 11 studies reported on all International Society for Cellular Therapy (ISCT) criteria for MSC characterization. Included randomized controlled trials were found to have some concerns (n = 2) to low (n = 4) risk of bias (RoB), while all non-randomized studies were found to have moderate (n = 5) RoB.
Interpretation: Our updated living systematic review concludes that MSCs can likely reduce mortality in patients with severe or critical COVID-19. A master protocol based on our Faster Approval framework appears necessary to facilitate the more accelerated accumulation of high-quality evidence that would reduce RoB, improve consistency in product characterization, and standardize outcome reporting.
Keywords: ARDS; COVID-19; MSC-EVs exosomes; SARS-CoV-2; acute respiratory distress syndrome; coronavirus disease 2019; extracellular vesicles; mesenchymal stem cells; mesenchymal stromal cells; microvesicles; pneumonia; sepsis; severe acute respiratory syndrome coronavirus 2.
【저자키워드】 COVID-19, SARS-CoV-2, Coronavirus disease 2019, ARDS, acute respiratory distress syndrome, Pneumonia, Mesenchymal stromal cells, Sepsis, Mesenchymal stem cells, Extracellular vesicles, Microvesicles, Severe acute respiratory syndrome coronavirus 2., MSC-EVs exosomes, 【초록키워드】 Randomized controlled trial, Treatment, coronavirus disease, Meta-analysis, Respiratory distress syndrome, Coronavirus disease 2019, ARDS, coronavirus, protocol, Master protocol, Mortality, acute respiratory distress syndrome, Mesenchymal stromal cells, systematic review, Sepsis, Mesenchymal stem cells, MSCs, Extracellular vesicles, Exosomes, Microvesicles, outcome, severe acute respiratory syndrome Coronavirus, Relative risk, heterogeneity, Patient, Control, death, Clinical studies, Critical, moderate, acute respiratory distress, clinical study, Evidence, Mesenchymal stromal cell, MSC, framework, Oxygenation, criteria, Hospital stay, respiratory distress, stromal cells, risk of death, Society, Consistency, acute respiratory syndrome, PROSPERO, Endpoint, Random-effects meta-analysis, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, approval, mean difference, treat, random-effects, controls, Extracellular, ISCT, reduce mortality, IMPROVE, identify, evaluate, reported, conducted, facilitate, appear, reduce, accelerate, accelerated, non-randomized study, random-effect, risk of bia, RoB, 【제목키워드】 review, Rapid, synthesis, stromal cell, Controlled,